ArticleCancer biomarkers : section A of Disease markers
A causal association between Epstein-Barr virus infection and lung cancer: A two-sample Mendelian Randomization study.
Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThe association between Epstein-Barr virus (EBV) and lung cancer risk remains controversial. Here, we used a two-sample Mendelian randomization (MR) analysis to test the causal relationship between EBV and lung cancer.MethodsData regarding lung cancer (outcomes) were collected from the Finnish database; the Genome-Wide Association Study (GWAS) summary-level dataset for EBV was obtained from the Open Forum Infect Dis. The inverse-variance weighted (IVW) method was used as a primary analytical approach; weighted median, MR-Egger, and weighted mode methods were used to ensure the robustness of the data. The MR-Egger regression assessed horizontal pleiotropy, and the MR pleiotropy residual sum and outlier (MR-PRESSO) method identified potential outliers. Cochran's Q test evaluated heterogeneity among instrumental variables (IVs).ResultsIVW analysis indicated several significant causal effects. Genetically elevated levels of EBV ZEBRA and EBNA-1 antibodies increased the risk of SQC (OR=1.26 and OR=1.33, respectively). Increased EBNA-1 antibodies also raised the risk of overall lung cancer and small cell lung cancer. Conversely, higher VCA p18 antibody levels were associated with a decreased risk of lung adenocarcinoma (OR=0.70). Sensitivity analyses suggested these findings were robust, with no significant evidence of horizontal pleiotropy or heterogeneity.ConclusionOur data suggests a causal effect between EBV and the progression of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.